Entrada Therapeutics(TRDA) - 2025 Q4 - Annual Results

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results -- Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 -- Expanding Preclinical Pipeline: The Company has generated compelling preclinical data from programs focused on ocular and metabolic diseases. The pipeline includes the advancement of two novel oligonucleotide-based programs for the potential treatment of inherited retinal diseases, where there exists high unmet need. The ...